Pictet Asset Management SA trimmed its position in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Rating) by 69.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 781,551 shares of the company’s stock after selling 1,792,764 shares during the quarter. Pictet Asset Management SA owned 1.84% of Neoleukin Therapeutics worth $805,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Walleye Capital LLC purchased a new stake in Neoleukin Therapeutics during the 1st quarter valued at $27,000. Kestra Private Wealth Services LLC boosted its holdings in shares of Neoleukin Therapeutics by 100.0% during the first quarter. Kestra Private Wealth Services LLC now owns 24,000 shares of the company’s stock worth $45,000 after purchasing an additional 12,000 shares during the period. Simon Quick Advisors LLC purchased a new stake in shares of Neoleukin Therapeutics during the second quarter worth about $49,000. Shay Capital LLC bought a new stake in shares of Neoleukin Therapeutics in the first quarter worth about $52,000. Finally, Adviser Investments LLC increased its holdings in Neoleukin Therapeutics by 39.7% during the 2nd quarter. Adviser Investments LLC now owns 65,404 shares of the company’s stock valued at $67,000 after purchasing an additional 18,587 shares during the period. 49.19% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on NLTX shares. Stifel Nicolaus cut Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 15th. HC Wainwright cut Neoleukin Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 16th. Canaccord Genuity Group cut Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 15th. Mizuho cut Neoleukin Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $21.00 to $2.00 in a research note on Tuesday, November 15th. Finally, Guggenheim cut Neoleukin Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 15th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Neoleukin Therapeutics has a consensus rating of “Hold” and an average target price of $6.00.
Neoleukin Therapeutics Stock Down 4.7 %
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
- Get a free copy of the StockNews.com research report on Neoleukin Therapeutics (NLTX)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.